• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pharmaceutical Innovation: Is It Really Rewarded? Product Image

Pharmaceutical Innovation: Is It Really Rewarded?

  • Published: June 2007
  • Region: World
  • 33 Pages
  • Decision Resources, Inc

FEATURED COMPANIES

  • Astellas
  • Chugai
  • Fujisawa
  • Genzyme
  • Merck & Co.
  • Novartis
  • MORE

Governments in the world’s largest pharmaceutical markets clearly have an interest in promoting access to innovative medicines, but the relatively high price of many novel drugs can place a heavy financial burden on overtaxed health care systems. Thus, the essential challenge for governments and other payers is to strike a balance between the benefits and costs of making innovative medicines more widely available.

Get the Answers You Need to Shape Your Strategy

- The European Commission wants to balance strict price controls and free market pricing. What initiatives has the EU undertaken to achieve this balance? Which EU markets have the strictest constraints on pharmaceutical pricing? Are new policies likely to improve or worsen the climate for pharmaceutical companies?
- Recently, the Japanese government has taken action intended to make premiums for innovation more generous and more attainable. What price reforms has the government made? Are they likely to in fact encourage innovation? Will the new price premiums be achievable?
- In the United States, the increasing focus on drug prices will prompt more payers to adopt evidence-based formularies. How is READ MORE >

Executive Summary
Strategic Considerations
Stakeholder Implications
Innovation: Balancing Benefits and Costs
European Union
High-Level Group on Innovation and the Provision of Medicines (G10 Medicines Group)
High-Level Pharmaceutical Forum
France
Standard Price-Setting Procedure
Price Setting for Innovative Drugs
Renewal of Pricing and Reimbursement
Germany
Reference Pricing
Prescribing Budgets
Health Technology Assessment
New Restrictions on the Use of Costly Drugs
Italy
Spain
Price Setting
Prior Authorization
More Selective Funding of Medicines
United Kingdom
Proposal to Replace the Pharmaceutical Price Regulation Scheme
National Institute for Clinical Excellence
Review of Variations in the Use of NICE-Approved Cancer Drugs
Patient Action Against Lack of Access to Certain Drugs
Accelerated NICE Appraisal Process
Japan
Initial Pricing of Branded Prescription Drugs
Similar-Efficacy Comparison Methods
Cost Calculation Method
Price Premiums
United States
Formulary Decision Making in the Private Sector
Medicare Sponsorship of Health Economic Research
Outlook and Implications for the Pharmaceutical Industry

Tables:
1. Methods Used for Pricing New Drugs in Japan, June 2002-March 2007
2. Hierarchy of National Health Insurance Price Premiums in Japan
3. Number of New Drugs Awarded Price Premiums for Therapeutic Advances,
June 2002-March 2007
4. U.S. Employers’ Views on Strategies to Increase Prescription Drug Benefit Value
5. U.S. Employers’ Views on Strategies to Increase Prescription Drug Benefit Value

Figures:
1. New Drugs’ Share of Total Pharmaceutical Expenditures in Major Markets, 2001-2004
2. Percentage of Drugs Awarded Various SMR Ratings in France
3. Percentage of Drugs Awarded Various ASMR Ratings in France
4. Criteria for Determining the Pricing Method Used for New Prescription Drugs in Japan

- Academy of Managed Care Pharmacy
- Agency for Healthcare Research and Quality
- Association of the British Pharmaceutical Industry
- Astellas
- Bayer
- Chugai
- Daiichi-Sankyo
- European Federation of Pharmaceutical Industries and Associations
- Federation of Pharmaceutical Manufacturers’ Associations of Japan
- Fujisawa
- Genentech
- Genzyme
- German Association of Research-Based Pharmaceutical Companies
- GlaxoSmithKline
- High-Level Group on Innovation and the Provision of Medicines (The G10 Medicines Group)
- Italian Pharmaceutical Agency
- Merck & Co.
- Mitsubishi
- Novartis
- Pfizer
- Pharmaceutical Forum
- Pharmaceutical Research and Manufacturers of America
- Roche
- Sanofi -Aventis
- Sanofi -Aventis Deutschland
- Schering-Plough
- Toyamakagaku

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos